CRISPR Therapeutics AG CRSP
50.04 USD -0.03 (-0.06%)
At closeNov 9, 2026, 7:33 PM EST
50.55 +0.51 +1.02%
After hours · Nov 9, 7:33 PM ET
48.71 Day range 51.52
44.12 52-week range 63.45
- YTD
- -4.58%
- 1 year
- -9.22%
News
benzinga.com CRISPR Therapeutics Reports 65% ANGPTL3 And 63% Triglyceride Reductions With CTX310 In Phase 1b Trial For Severe Hypertriglyceridemia; Well Tolerated, With No Treatment-Related Serious Adverse Events And No Clinically Relevant Elevations In Liver Transaminases -Data presented in a late-breaking oral presentation at AHA--A single-course treatment with CTX310 produced a mean reduction from baseline of 65% in circulating ANGPTL3 and 63% in triglycerides (TG)…
benzinga.com Reported Sunday, CRISPR Therapeutics Reports 83% Of Systemic Sclerosis Patients Achieved rCRISS-25 Response At Month 3 With Zugo-Cel, As All Nine Myositis Patients Achieve Moderate Or Major TIS Response Systemic sclerosis (SSc) data presented at ACR Convergence 2026 showed 83% (5/6) of patients receiving standard lymphodepletion achieved a clinical response (rCRISS-25) at Month 3, with all…- benzinga.com Citigroup Maintains Buy on CRISPR Therapeutics, Raises Price Target to $90 Citigroup analyst Yigal Nochomovitz maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and raises the price target from $88 to $90.
- benzinga.com Wells Fargo Maintains Equal-Weight on CRISPR Therapeutics, Lowers Price Target to $70 Wells Fargo analyst Yanan Zhu maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Equal-Weight and lowers the price target from $75 to $70.
globenewswire.com CRISPR Therapeutics to Present Clinical Data from Zugo-cel in Large B-Cell Lymphoma at the 68th American Society of Hematology (ASH) Annual Meeting and Exposition ZUG, Switzerland and BOSTON, Nov. 04, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP) today announced that clinical data in patients with relapsed or refractory large B-cell lymphoma from…
zacks.com CRSP's Q3 Loss Wider Than Expected, Sales Beat Estimates CRISPR Therapeutics reports higher-than-expected Q3 sales as Casgevy sales surge, while expanding pediatric approvals and advancing multiple clinical programs.
zacks.com CRISPR Therapeutics AG (CRSP) Reports Q3 Loss, Tops Revenue Estimates CRISPR Therapeutics AG (CRSP) came out with a quarterly loss of $1.15 per share versus the Zacks Consensus Estimate of a loss of $1.06. This compares to a loss of $1.17 per share a year ago.
fool.com Casgevy Starts Paying Off for CRISPR: Rapid Earnings Reaction CRISPR's first approved therapy is gaining traction, but the company's finances still lean on its cash reserves and an expensive pipeline.
benzinga.com CRISPR Therapeutics Q3 EPS $(1.15) Misses $(0.98) Estimate, Sales $12.669M Beat $10.495M Estimate CRISPR Therapeutics (NASDAQ:CRSP) reported quarterly losses of $(1.15) per share which missed the analyst consensus estimate of $(0.98) by 17.35 percent. This is a 1.71 percent increase over losses…
globenewswire.com CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2026 Financial Results – CASGEVY® revenue of $99 million in the third quarter of 2026, up 30% quarter-over-quarter and nearly six times the third quarter of 2025 – – CASGEVY approved in the U.K. for children 5 years of age…
zacks.com CRISPR Therapeutics AG (CRSP) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release CRISPR Therapeutics (CRSP) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
globenewswire.com CRISPR Therapeutics Announces the Appointment of Siva Sakhamuri, Ph.D., as Chief Technical Officer ZUG, Switzerland and BOSTON, Nov. 02, 2026 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), today announced the appointment of Sivakesava (Siva) Sakhamuri, Ph.D., as Chief Technical Officer,…- benzinga.com CRISPR Therapeutics Appoints A. J. Silver CFO, Effective Immediately, Succeeding Raju Prasad CRISPR Therapeutics (NASDAQ:CRSP) today announced that its Chief Financial Officer, Raju Prasad, Ph.D., will be stepping down from the Company to pursue external opportunities, and A.J. Silver, the…
benzinga.com UBS Initiates Coverage On CRISPR Therapeutics with Neutral Rating, Announces Price Target of $52 UBS analyst Joon Lee initiates coverage on CRISPR Therapeutics (NASDAQ:CRSP) with a Neutral rating and announces Price Target of $52.
benzinga.com Cathie Wood Claps Back After Being Confronted as ARKK Fell Nearly 15% While QQQ Soared 112% in Five Years — Calls It an ‘Incorrect Comparison’ Cathie Wood defends ARKK's 15% drop vs QQQ's 112% 5-year gain, calling it an 'incorrect comparison' and blaming 'endpoint sensitivity.'
benzinga.com Cathie Wood Says AI Revolution Could Supercharge Global Growth — TSLA, COIN and CRSP Stocks Are Among Her Top Bets Cathie Wood explains why Tesla, Coinbase, and CRISPR lead her "Rapid Real Growth" thesis as 5 tech platforms transform global GDP.
benzinga.com Next Biotech Boom May Be Cancer Vaccines: Watch These ETFs Moderna’s cancer vaccine breakthrough puts biotech, mRNA and genomics ETFs in focus. Here are the funds worth watching.- benzinga.com Citizens Reiterates Market Outperform on CRISPR Therapeutics, Maintains $80 Price Target Citizens analyst Silvan Turkcan reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Market Outperform and maintains $80 price target.
benzinga.com CRISPR Therapeutics Data From Its Phase 1 Clinical Study Of CTX Shows 79% Mean Reductions From Baseline For ANGPTL3, 48% Maximum For Triglycerides CRISPR Therapeutics (NASDAQ:CRSP) today presented durability data from its Phase 1a clinical trial evaluating CTX310®, an investigational, in vivo CRISPR/Cas9 gene editing therapy targeting ANGPTL3.…
benzinga.com Citizens Reiterates Market Outperform on CRISPR Therapeutics, Maintains $80 Price Target Citizens analyst Silvan Turkcan reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Market Outperform and maintains $80 price target.
benzinga.com Recursion, Novavax and Crispr Stocks Trending in Pre-Market—Here's Why Recursion, Novavax and Crispr Therapeutics slip in premarket trading after surging Wednesday on positive cancer therapy trial results.
benzinga.com Moderna Stock Cools Off After-Hours, Following Massive 177% Cancer Vaccine Rally — Merck, Pfizer and BioNTech Among mRNA Names Trending Tonight Healthcare stocks saw mixed after-hours moves, with Moderna and Merck cooling after explosive gains on positive cancer trial results.
benzinga.com Estee Lauder, Moderna, Merck And Other Big Stocks Moving Higher On Wednesday Dow Jones up 200 points on Wed. Estee Lauder & other top stocks record gains after reporting strong Q4 results and positive sales guidance.
benzinga.com Citigroup Maintains Buy on CRISPR Therapeutics, Raises Price Target to $88 Citigroup analyst Yigal Nochomovitz maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and raises the price target from $82 to $88.- benzinga.com CRISPR Therapeutics Q2 EPS $(0.94) Beats $(1.17) Estimate, Sales $10.181M Beat $6.789M Estimate CRISPR Therapeutics (NASDAQ:CRSP) reported quarterly losses of $(0.94) per share which beat the analyst consensus estimate of $(1.17) by 19.66 percent. This is a 60.83 percent increase over losses of…
- benzinga.com HC Wainwright & Co. Reiterates Buy on CRISPR Therapeutics, Maintains $80 Price Target HC Wainwright & Co. analyst Mitchell S. Kapoor reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and maintains $80 price target.
- benzinga.com Citizens Reiterates Market Outperform on CRISPR Therapeutics, Maintains $80 Price Target Citizens analyst Silvan Turkcan reiterates CRISPR Therapeutics (NASDAQ:CRSP) with a Market Outperform and maintains $80 price target.
benzinga.com Rivian Automotive, Tenax Therapeutics, Robinhood And Other Big Stocks Moving Higher On Thursday Rivian Automotive Inc (RIVN) gained 12.2% after strong Q2 production figures and raised delivery forecast. Other companies such as Nexa Resources SA (NEXA) and Moderna Inc (MRNA) also saw gains in…
benzinga.com 10 Health Care Stocks With Whale Alerts In Today’s Session This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity…
benzinga.com Investors Flee Cathie Wood's ARKK ETF As It Trails S&P 500, Nasdaq 100 By Far Cathie Wood’s ARK Innovation ETF is shedding assets this year as it continues to underperform the technology-heavy Nasdaq 100 Index.- benzinga.com Bernstein Maintains Market Perform on CRISPR Therapeutics, Raises Price Target to $56 Bernstein analyst William Pickering maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Market Perform and raises the price target from $50 to $56.
benzinga.com Citigroup Maintains Buy on CRISPR Therapeutics, Raises Price Target to $82 Citigroup analyst Yigal Nochomovitz maintains CRISPR Therapeutics (NASDAQ:CRSP) with a Buy and raises the price target from $80 to $82.
benzinga.com FreightCar America Posts Downbeat Q4 Results, Joins BioNTech, PROG Holdings And Other Big Stocks Moving Lower In Tuesday's Pre-Market Session US stock futures lower, FreightCar America (RAIL) plunges after weak earnings. Other stocks moving lower in pre-market trading.
benzinga.com What's Going On With Moderna, Capricor, Other Biotech Stocks On Monday? FDA biologics chief Vinay Prasad will leave in April, lifting biotech stocks such as uniQure, Capricor, Moderna, and raising hopes for smoother drug approvals.
benzinga.com Cathie Wood Has 13 Big Ideas For 2026: Here's The Ark Invest List And Stocks To Watch Ark Invest, led by Cathie Wood, issued another "Big Ideas" list on Wednesday, sharing themes for 2026 that investors should watch.
benzinga.com Positive China Trial Data Moves HUTCHMED Closer To Rare Blood Disorder Drug Filing In 2026 HUTCHMED reported positive Phase 3 trial results for sovleplenib in autoimmune anemia, supporting a planned China drug filing in 2026 as competition in blood disorders intensifies.
benzinga.com Cathie Wood's Biotech Trend: Twist, Beam, CRISPR Latest Stock Picks The massive rotation currently unfolding within ARK Invest suggests that Cathie Wood thinks 2026 will be the year of the genomic revolution.
benzinga.com Intellia Freezes Key Trial After Serious Liver Event, Stock Tumbles Intellia Therapeutics (NASDAQ: NTLA) paused their Phase 3 MAGNITUDE and MAGNITUDE-2 trials after a serious liver-related adverse event.- benzinga.com 10 Health Care Stocks Whale Activity In Today's Session
benzinga.com My Top Biotech Stock Picks And Portfolio Strategy For The Next 3-10 Years Forecasts in biotech market indicate that by 2030, gene therapy will become more accessible, potentially generating hundreds of billions dollars in revenue.
benzinga.com Independent Bank Posts Upbeat Earnings, Joins Blaize Holdings, Interactive Brokers Group And Other Big Stocks Moving Higher On Friday U.S. stocks were mixed, with the Dow Jones index falling around 50 points on Friday.
benzinga.com 44 Public Companies Make Time's Most Influential List: Coinbase, UFC, Nintendo, Netflix And More Stocks Investors Can Buy The 2025 TIME 100 Most Influential Companies list includes over 40 companies that investors can buy stock in.
benzinga.com Eli Lilly's $1.3 Billion Verve Deal Signals Confidence In Gene Editing Space: Analyst Lilly's Verve acquisition lifts sentiment in gene editing stocks, with analysts calling it a strategic and timely move in a tough funding climate.
benzinga.com Jabil Posts Upbeat Earnings, Joins Verve Therapeutics, John Wiley & Sons And Other Big Stocks Moving Higher On Tuesday 
benzinga.com Vinay Prasad's Appointment To FDA's CBER Triggers Questions Over Future Of Cell And Gene Therapy Regulation FDA names Vinay Prasad to lead CBER, raising questions over biologics oversight and triggering biotech stock losses and analyst concerns.- benzinga.com 'FDA Names Vinay Prasad as New Head of Vaccines, Biologics'- Bloomberg Law https://news.bloomberglaw.com/health-law-and-business/fda-names-vinay-prasad-as-new-head-of-vaccines-biologics
benzinga.com This Bath & Body Works Analyst Turns Bullish; Here Are Top 5 Upgrades For Tuesday 
benzinga.com WeRide, CRISPR And GeneDx Are Among Top 10 Mid-Cap Gainers Last Week (Feb 10-Feb 14): Are The Others In Your Portfolio? Top performing mid-cap stocks last week: WRD (+97.62%), GDS (+43.45%), SWTX (+42.58%), RXRX (+40.59%), SOC (+39.09%), WGS (+28.23%), VNET (+28.22%), NSP (+25.99%), CRSP (+25.21%), AXSM (+24.01%)
benzinga.com This Roku Analyst Turns Bullish; Here Are Top 5 Upgrades For Friday 
benzinga.com Gilead Sciences, Upstart, Mercury General, Confluent And Other Big Stocks Moving Higher On Wednesday